Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 21.30
HPTX's Cash to Debt is ranked higher than
75% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. HPTX: 21.30 )
HPTX' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 21.3

Equity to Asset 0.50
HPTX's Equity to Asset is ranked higher than
63% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. HPTX: 0.50 )
HPTX' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.87
Current: 0.5

0.5
0.87
F-Score: 4
Z-Score: 2.50
M-Score: 7.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 20.43
HPTX's Operating margin (%) is ranked higher than
92% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. HPTX: 20.43 )
HPTX' s 10-Year Operating margin (%) Range
Min: -31.79   Max: -31.79
Current: 20.43

Net-margin (%) 21.30
HPTX's Net-margin (%) is ranked higher than
94% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. HPTX: 21.30 )
HPTX' s 10-Year Net-margin (%) Range
Min: 39.4   Max: 39.4
Current: 21.3

ROE (%) 12.81
HPTX's ROE (%) is ranked higher than
92% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. HPTX: 12.81 )
HPTX' s 10-Year ROE (%) Range
Min: -93.82   Max: 13.89
Current: 12.81

-93.82
13.89
ROA (%) 6.39
HPTX's ROA (%) is ranked higher than
91% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. HPTX: 6.39 )
HPTX' s 10-Year ROA (%) Range
Min: -361.29   Max: 11.67
Current: 6.39

-361.29
11.67
ROC (Joel Greenblatt) (%) 1754.26
HPTX's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. HPTX: 1754.26 )
HPTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -137678.95   Max: -1433.44
Current: 1754.26

-137678.95
-1433.44
» HPTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

HPTX Guru Trades in Q1 2013

RS Investment Management 74,900 sh (New)
Steven Cohen 125,000 sh (New)
Louis Moore Bacon 15,000 sh (New)
» More
Q2 2013

HPTX Guru Trades in Q2 2013

Steven Cohen Sold Out
Louis Moore Bacon Sold Out
RS Investment Management 73,078 sh (-2.43%)
» More
Q3 2013

HPTX Guru Trades in Q3 2013

RS Investment Management Sold Out
» More
Q2 2014

HPTX Guru Trades in Q2 2014

Jim Simons 34,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with HPTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.00
HPTX's P/E(ttm) is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 28.00 )
HPTX' s 10-Year P/E(ttm) Range
Min: 18.87   Max: 177.55
Current: 28

18.87
177.55
P/B 3.45
HPTX's P/B is ranked higher than
82% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. HPTX: 3.45 )
HPTX' s 10-Year P/B Range
Min: 3.09   Max: 5.76
Current: 3.45

3.09
5.76
P/S 5.98
HPTX's P/S is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. HPTX: 5.98 )
HPTX' s 10-Year P/S Range
Min: 5.36   Max: 516.4
Current: 5.98

5.36
516.4
PFCF 15.96
HPTX's PFCF is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 15.96 )
HPTX' s 10-Year PFCF Range
Min: 14.32   Max: 40.65
Current: 15.96

14.32
40.65
EV-to-EBIT 21.91
HPTX's EV-to-EBIT is ranked higher than
93% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 21.91 )
HPTX' s 10-Year EV-to-EBIT Range
Min: 20.1   Max: 25.9
Current: 21.91

20.1
25.9
Current Ratio 3.38
HPTX's Current Ratio is ranked higher than
69% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. HPTX: 3.38 )
HPTX' s 10-Year Current Ratio Range
Min: 0.11   Max: 11.32
Current: 3.38

0.11
11.32
Quick Ratio 3.31
HPTX's Quick Ratio is ranked higher than
70% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. HPTX: 3.31 )
HPTX' s 10-Year Quick Ratio Range
Min: 0.11   Max: 11.27
Current: 3.31

0.11
11.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.40
HPTX's Price/Median PS Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. HPTX: 0.40 )
HPTX' s 10-Year Price/Median PS Value Range
Min: 0.41   Max: 34.43
Current: 0.4

0.41
34.43
Earnings Yield (Greenblatt) 4.60
HPTX's Earnings Yield (Greenblatt) is ranked higher than
75% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. HPTX: 4.60 )
HPTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.9   Max: 5
Current: 4.6

3.9
5

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0HY.Germany
Hyperion Therapeutics Inc was incorporated under the laws of the State of Delaware in November 2006. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company's product candidate, Ravicti (glycerol phenylbutyrate), is designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. It is developing Ravicti to treat two different diseases in which blood ammonia is elevated: the prevalent urea cycle disorders, or UCD, and hepatic encephalopathy, or HE. UCD are inherited rare genetic diseases caused by a deficiency of one or more enzymes or protein transporters that constitute the urea cycle, which in a healthy individual removes ammonia through the conversion of ammonia to urea. HE may develop in some patients with liver scarring, known as cirrhosis, or acute liver failure and is a chronic disease which fluctuates in severity and may lead to serious neurological damage. The Company's strategy is to commercialize a product portfolio, including Ravicti, for the treatment of UCD and to develop Ravicti for the treatment of HE and other indications. Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price; Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd's worldwide rights to BUPHENYL and, subject to certain conditions, AMMONUL.
» More Articles for HPTX

Headlines

Articles On GuruFocus.com


More From Other Websites
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% Sep 16 2014
PTC Therapeutics (PTCT) Soars: Stock Adds 11.5% is Session Sep 16 2014
Hyperion Therapeutics (HPTX) Upgraded From Hold to Buy Sep 11 2014
Avanir Pharmaceuticals (AVNR) in Focus: Stock Surges 14.4% Sep 11 2014
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Hyperion Therapeutics, Inc.... Sep 10 2014
UPDATE: JMP Securities Reiterates On Hyperion Therapeutics Inc As Diabetes Program Is Discarded Sep 09 2014
Infinity Pharmaceuticals (INFI) Soars: Stock Rises 7.1% Sep 09 2014
Ignyta (RXDX) Jumps: Stock Adds 5.9% in Session Sep 09 2014
Clal Bio Falls as Hyperion Alleges Misconduct at Unit Sep 09 2014
Hyperion reports diabetes drug misconduct Sep 08 2014
Hyperion reports diabetes drug misconduct Sep 08 2014
Evotec profit target in danger after drug trial halted Sep 08 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Material Impairments, Other Events, Financial... Sep 08 2014
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Hyperion... Sep 08 2014
Evotec takes charge for end of diabetes drug development Sep 08 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Hyperion... Sep 08 2014
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Hyperion... Sep 08 2014
US STOCKS-Futures pointing to modest losses at the open Sep 08 2014
Hyperion stops diabetes drug development, shares fall Sep 08 2014
[$$] Hyperion Ends Diabetes Drug Development After Misconduct Sep 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK